Comparison · NCT04550936-dd12c425
Invasive Aspergillosis vs Mucormycosis: Number of Participants With Serious Adverse Event at Week 24
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Invasive Aspergillosis vs Mucormycosis: Number of Participants With Serious Adverse Event at Week 24. Trial comparisons, record NCT04550936-dd12c425. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04550936-dd12c425
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.169 | 0.124 | 0.227 | wilson | |
| Risk in group 2 | 0.176 | 0.0619 | 0.41 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00732 | -0.246 | 0.121 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.959 | 0.328 | 2.8 | log | |
| Odds ratio, group 1 over group 2 | 0.95 | 0.259 | 3.49 | log | |
| Number needed to treat, for one fewer participant with the outcome on Invasive Aspergillosis than on Mucormycosis | 137 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Invasive Aspergillosis | Participants with aspergillosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group. | 34 | 201 | OG000 |
| Group 2 | Mucormycosis | Participants with mucormycosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group. | 3 | 17 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Number of Participants With Serious Adverse Event at Week 24
- Description
Serious adverse event = any untoward medical occurrence at any dose that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of hospitalization, or resulted in persistent or significant disability/incapacity or congenital anomaly/birth defect. Number of participants with any serious adverse event based on the medical records at Week 24 post index date were reported in this outcome measure. Index date was defined as date of Isavuconazole treatment initiation anytime in between 15 October 2015 until 30 June 2019.
- Time frame
- Week 24 post index date (retrospective data extracted and evaluated from study start date and until study completion, approximately 34 months)
- Population
- Analysis population included all eligible participants whose data was retrieved and analyzed in this study.
Source ClinicalTrials.gov
Trial
- Title
- A Study to Understand How the Use of Paxlovid Affected the Healthcare Use in People With Pre-existing Conditions.
- NCT number
- NCT04550936
- Phases
- Conditions
- Invasive Aspergillosis, Mucormycosis
- Interventions
- Isavuconazole
- Lead sponsor
- Pfizer
- Results first posted
- 2025-12-09
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04550936?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04550936-dd12c425